ASCO Direct LatAm Summit

MEXICO CITY, SEPTEMBER 3 - 5, 2024

GET YOUR ACCESS

About this Summit

The ASCO Direct™ LatAm Summit is planned to be a yearly Latin American Scientific Summit in specific oncology areas of interest (adapting every year according to that moment’s educational needs), licensed by the American Society of Clinical Oncology (ASCO®), one of the largest and most respected Medical Societies in the world, and leader in the field of Oncology.

This first Summit will take place in Mexico City, in the subsequent years will be hosted in other Latin American cities, and this first Summit will have the Mexican Society of Clinical Oncology as Scientific Partner

2024 topics: covering most recent scientific advances by the American Society of Clinical Oncology (ASCO), in the following areas:
- Breast cancer
- Lung cancer
- Gastrointestinal cancer

Why should you attend?

All lectures in this Summit will be presented by the original international speakers from ASCO official conferences.

Live streaming (and on demand) to all Latin American countries. On-demand content will be available for 6 months after the Summit

Audio in Spanish, English and Portuguese.

The Consejo Mexicano de Oncología has accredited this educational program with 22 certification points

national-cancer-institute-jeT_DE3esSI-unsplash_edited.jpg

Scientific Agenda

Scientific agenda:
- See complete agenda below

Round tables in each cluster:
- ASCO speakers and LatAm experts appointed & coordinated by SMEO will discuss the scientific content and its impact in LatAm reality

Scientific Committee

Chairman

Pere Gascón, MD

Director, Laboratory of Molecular and Translational Oncology; Director, Chair for Oncology and Multidisciplinary Knowledge; Former Director Division of Medical Oncology. Hospital Clínic, Barcelona

Jaffer Ajani, MD

Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center.
GI Scientific Committee

Scott Kopetz, MD

Professor, AVP Translational Integration.

MD Anderson Cancer Center.
GI Scientific Committee

Josep Tabernero, MD

Head, Medical Oncology Department
Director, Vall d’Hebron Institute of Oncology (VHIO)
Professor of Medicine,
Vall d’Hebron University Hospital (HUVH)
GI Scientific Committee

Enriqueta Felip, MD

Section in Chief, Oncology Department, Director Thoracic Oncology Unit
Vall d’Hebron University Hospital & Vall d’Hebron Institute of Oncology (VHIO).
Lung Scientific Committee

Suresh Ramalingam, MD

Executive Director
Winship Cancer Institute
Roberto C. Goizueta Chair for Cancer Research
Emory University School of Medicine
Lung Scientific Committee

Luis Raez, MD

Chief Scientific Officer & Medical Director
Memorial Cancer Institute/Memorial Health Care System
Co-Director MCI/FAU Florida Cancer Center of Excellence
Lung Scientific Committee

Javier Cortés, MD

Head, International Breast Cancer Center (IBCC), Barcelona. Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid
Breast Scientific Committee

Hope Rugo, MD

Professor of Medicine and Winterhof Distinguished Family Professor of Breast Oncology
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco.
Breast Scientific Committee

Erica Mayer, MD

Director of Clinical Research and Institute Physician in the Breast Oncology Center at the Dana-Farber Cancer Institute. Associate Professor in Medicine at Harvard Medical School.
Breast Scientific Committee

SMEO LatAm Experts Coordinating Committee

Sinuhé Barroso, MD

President, Mexican Society of Oncology

Yanin Chávarri, MD

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán.
ASCO Latin America Regional Council Chair

Paula Cabrera, MD

National Institute of Cancerology
Vice President, Mexican Society of Oncology

Enrique Bargalló, MD

Director, Breast Cancer Center
National Institute of Cancerology

Claudio Martin, MD

Head of the Thoracic Oncology Department, Alexander
Fleming Institute, Argentina.
Lung Panel

Oscar Arrieta, MD

General Director, National Institute of Cancerology,
Mexico.
Lung Panel

Cynthia Villareal, MD

Clinical Oncology Director at Breast Cancer Center, Hospital Zambrano Hellion, Mexico. Breast Panel

Mariana Chavez McGregor, MD

Associate Professor, Tenured, Department
of Health Services Research, Division of OVP, Cancer Prevention and
Population Sciences. The University of Texas MD Anderson Cancer Centre.
Breast Panel

Laura Torrecillas Torres, MD

Head of the Division of Neoplastic Conditions,
ISSSTE 20 de Noviembre National Medical Center, Mexico.
GI Panel

Erika Ruiz, MD

Translational Oncology Laboratory, National Institute of
Cancerology Mexico.
GI Panel

Snapinsta.app_315237294_5638609602899624_3543964005028004085_n_1080.jpg

Where & when

September 3-5, 2024
WTC Mexico City: Live event
Live Streaming: all Latin American countries

Sept. 3: registration, pre symposium
Sept. 4: scientific sessions all day
Sept. 5: scientific sessions in the morning, adjournment afternoon

Admission pricing

Live or online attendance:

USD$250.00: ASCO or Local Oncology Society members
USD$275.00: Non-ASCO or non-Society Oncologist

Scientific Agenda

September 3, 2024:
- 3:00-3:15 Inauguration
- 3:15-3:45 Use of circulating tumor DNA in GI cancers. Dr. Scott Kopetz
- 3:45-4:00 Q&A
- 4:00-4:30 New targets and therapeutic opportunities in metastatic colorectal cancer. Dr. Josep Tabernero
- 4:30-4:45 Q&A
- 4:45-5:05 Break
- 5:05-5:35 Evolving therapy of esophageal and GEJ. Dr. Ajani Jafer
- 5:35-5:50 Q&A
- 5:50-6:20 Strategies for treatment of liver limited metastatic disease in colorectal cancer. Dr. Scott Kopetz
- 6:20-6:35 Q&A
- 6:35-7:05 New immunotherapy strategies for microsatellite stable (MSS) colorectal cancer. Dr. Josep Tabernero
- 7:05-7:20 Q&A

September 4, 2024:
- 9:00-9:30 Novel targets in gastric and esophageal adenocarcinoma. Dr. Ajani Jafer
- 9:30-9:40 Q&A
- 9:40-10:40 Round Table GI Cancer: Drs. Kopetz, Tabernero, Jafer and LatAm oncologists: Dr. Laura Torrecillas and Dr. Erika Ruiz (both from Mexico)
- 10:40-11:00 Break
- 11:00-11:30 Targeted Therapy for early stage NSCLC. Dra. Enriqueta Felip
- 11:30-11:40 Q&A
- 11:40-12:10 Locally advanced NSCLC: Results from LAURA, PACIFIC 1 & 2 Clinical Trials. Dr. Ramalingam Suresh
- 12:10-12:20 Q&A
- 12:20-12-50 Perioperative Immunotherapy for NSCLC. Dr. Luis Raez
- 12:50-13:00 Q&A
- 13.00-15:00 Lunch
- 15:00-15:30 Lung Cancer: First Line Immunotherapy for metastatic disease. Dr. Ramalingam Suresh

September 4, 2024 (continued):
- 15:30-15:40 Q&A
- 15:40-16:10 Antibody Drug Conjugates (ADCs) and other options after Immunotherapy failure in NSCLC. Dr. Enriqueta Felip
- 16:10-16:20 Q&A
- 16:20- 16:50 Metastatic NSCLC: Updates in Targeted Therapy (EGFR, ALK, ROS, RET, KRAS, NTRK). Dr. Luis Raez
- 16:50-17:00 Q&A
- 17:00-17:20 Break
- 17:20-18:20 Round Table Lung Cancer with Drs. Felip, Ramalingam, Raez and LatAm oncologists: Dr. Oscar Arrieta (Mexico) and Dr. Claudio Martin (Argentina)
- 18:20-18:50 Highlights of ASCO – Neo Adjuvant treatment in locoregional breast cancer. Dr. Javier Cortes
- 18:50-19:00 Q&A

September 5, 2024:
- 9:00-9:30 Pregnancy and fertility concerns in young breast cancer patients. Dr. Erica Mayer
- 9:30-9:40 Q&A
- 9:40-10:10 Highlights of ASCO – Metastatic breast cancer. Dr.Hope Rugo
- 10:10-10:20 Q&A
- 10:20-10:50 Escalation and de-escalation strategies in HER2+Breast Cancer. Dr. Javier Cortes
- 10:50-11:00 Q&A
- 11:00-11:15 Break
- 11:15-11:45 Use of CDK4/6i in early and advanced breast cancer patients. Dr. Erica Mayer
- 11:45-11:55 Q&A
- 11:55-12:25 Antibody Drug Conjugates (ADCs) in Breast Cancer. Current and future perspectives. Dr. Hope Rugo
- 12:25-12:35 Q&A
- 12:35-13:30 Round Table Breast Cancer with Drs. Cortes, Rugo, Mayer and LatAm oncologists: Dr. Carlos Barrios (Brazil) and Dr. Mariana Chavez (MD Anderson)

MEXICO CITY, SEPTEMBER 3 - 5, 2024

About this Summit

Why should you attend?

All lectures in this Summit will be presented by the original international speakers from ASCO official conferences.

​

Live streaming (and on demand) to all Latin American countries. On-demand content will be available for 6 months after the Summit

​

Audio in Spanish, English and Portuguese.

​

The Consejo Mexicano de Oncología has accredited this educational program with 22 certification points

​

​

Scientific Agenda

Scientific Committee

Chairman

SMEO LatAm Experts Coordinating Committee

Where & when

Admission pricing

Scientific Agenda

Scientific Partner